Abstract
Smad7 is an inhibitory Smad protein that blocks Transforming Growth Factor-beta (TGF-β) signaling through a negative feedback loop, also capable of mediating the crosstalk between TGF-β and other signaling pathways. Smad7 mRNA and protein levels are upregulated after TGF-β signaling; subsequently, Smad7 protein binds TGF-β type I receptor blocking R-Smad phosphorylation and eventually TGF-β signaling. Because of this inhibitory function, Smad7 can antagonize diverse cellular processes regulated by TGF-β such as cell proliferation, differentiation, apoptosis, adhesion and migration. Smad7 induction by different cytokines, besides TGF-β, is also critical for crosstalk/integration of a variety of signaling pathways, and relevant in the pathology of some diseases. Thus, Smad7 plays a key role in the control of various physiological events, and even in some pathological processes including fibrosis and cancer. This review highlights the main known functions of Smad7 with a particular focus on the relevance that alterations of Smad7 function may have in homeostasis, also describing some Smad7 emerging roles in the development of several human diseases that identify this protein as a potential therapeutic target.
Keywords: ALK5, cancer, fibrosis, Smad, Smad7, TGF, POSTTRANSLATIONAL MODIFICATIONS, SIGNALING PATHWAYS, cell proliferation, apoptosis
Current Molecular Pharmacology
Title: Inhibitory Smad7: Emerging Roles in Health and Disease
Volume: 4
Author(s): Marco A. Briones-Orta, Angeles C. Tecalco-Cruz, Marcela Sosa-Garrocho, Cassandre Caligaris and Marina Macias-Silva
Affiliation:
Keywords: ALK5, cancer, fibrosis, Smad, Smad7, TGF, POSTTRANSLATIONAL MODIFICATIONS, SIGNALING PATHWAYS, cell proliferation, apoptosis
Abstract: Smad7 is an inhibitory Smad protein that blocks Transforming Growth Factor-beta (TGF-β) signaling through a negative feedback loop, also capable of mediating the crosstalk between TGF-β and other signaling pathways. Smad7 mRNA and protein levels are upregulated after TGF-β signaling; subsequently, Smad7 protein binds TGF-β type I receptor blocking R-Smad phosphorylation and eventually TGF-β signaling. Because of this inhibitory function, Smad7 can antagonize diverse cellular processes regulated by TGF-β such as cell proliferation, differentiation, apoptosis, adhesion and migration. Smad7 induction by different cytokines, besides TGF-β, is also critical for crosstalk/integration of a variety of signaling pathways, and relevant in the pathology of some diseases. Thus, Smad7 plays a key role in the control of various physiological events, and even in some pathological processes including fibrosis and cancer. This review highlights the main known functions of Smad7 with a particular focus on the relevance that alterations of Smad7 function may have in homeostasis, also describing some Smad7 emerging roles in the development of several human diseases that identify this protein as a potential therapeutic target.
Export Options
About this article
Cite this article as:
A. Briones-Orta Marco, C. Tecalco-Cruz Angeles, Sosa-Garrocho Marcela, Caligaris Cassandre and Macias-Silva Marina, Inhibitory Smad7: Emerging Roles in Health and Disease, Current Molecular Pharmacology 2011; 4 (2) . https://dx.doi.org/10.2174/1874467211104020141
DOI https://dx.doi.org/10.2174/1874467211104020141 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Somatic Genomic Variations in Extra-Embryonic Tissues
Current Genomics Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters The Faulty Perinatal Hormonal Imprinting as Functional Teratogen
Current Pediatric Reviews Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets Gene Selection in Multi-class Imbalanced Microarray Datasets Using Dynamic Length Particle Swarm Optimization
Current Bioinformatics Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery